Journal: Exploration of Targeted Anti-tumor Therapy
Article Title: Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
doi: 10.37349/etat.2022.00111
Figure Lengend Snippet: Clinical trials with TAA and neoantigens-based cancer vaccines encoding
Article Snippet: Skin , Melanoma Stage IIIB, C, and IV , Phase I (Lipo-MERIT trial) , FixVac (BNT 111) , 4 TAA (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) , Liposomal RNA (RNA-LPX) vaccine , Strong CD4 + and CD8 + T-cell immunity against the vaccine antigens/antigen-specific cytotoxic T-cell responses in some responders reach magnitudes and are durable , BioNTech SE (Germany) , NCT02410733 , [ ] .
Techniques: Clinical Proteomics, Immunopeptidomics, Vaccines, Formulation, Recombinant, Modification, Virus, Adjuvant, Mutagenesis, Ex Vivo